SK Biopharmaceuticals Forms Strategic Research Collaboration with ProEn Therapeutics to Advance Radiopharmaceutical Oncology Pipeline

SK Biopharmaceuticals, a biotech company focusing on the research, development and commercialization of treatments for disorders of the central nervous sys...

December 17, 2024 | Tuesday | News
EMA Committee Issues Positive Opinion for Long-Acting HIV Treatment Vocabria + Rekambys for Adolescents

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, ...

December 17, 2024 | Tuesday | News
Merck Discontinues Clinical Development of Vibostolimab and Favezelimab in Oncology Trials

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programs for vibostolima...

December 17, 2024 | Tuesday | News
Menarini, Stemline, and MEDSIR Unveil Groundbreaking ADELA Trial for Advanced ER+/HER2- Breast Cancer at SABCS 2024

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...

December 16, 2024 | Monday | News
Jaypirca® (Pirtobrutinib) Gains Approval in China for Relapsed or Refractory Mantle Cell Lymphoma

Jaypirca®, a highly selective kinase inhibitor, utilizes a novel non-covalent binding mechanism to re-establish BTK inhibition in mantle cell lymphoma ...

December 16, 2024 | Monday | News
Eli Lilly's Omvoh® (Mirikizumab) Receives Positive CHMP Opinion for Crohn’s Disease in the EU

Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

December 16, 2024 | Monday | News
Merck’s WELIREG® Receives Positive CHMP Opinion for VHL Disease-Associated Tumors and Advanced RCC in the EU

Positive CHMP opinion brings us closer to offering WELIREG, a first-in-class HIF-2α inhibitor, to certain patients in the European Union, in order to...

December 16, 2024 | Monday | News
A2A Pharmaceuticals Advances Phase 1 Clinical Trial of TACC3 Inhibitor A0-252 in Ovarian, TNBC, and Endometrial Cancers

A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies,...

December 13, 2024 | Friday | News
Imlunestrant Shows Significant PFS Improvement in Phase 3 EMBER-3 Trial for ER+ HER2- Advanced Breast Cancer

Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen recept...

December 13, 2024 | Friday | News
Shaping Biopharma Purification: Phenomenex’s Vision for 2025

Matt Boag, Biopharmaceutical Product Marketing Manager at Phenomenex, discusses the transformative innovations shaping plasmid DNA, mRNA, and peptide purif...

December 12, 2024 | Thursday | Opinion
Redefining Precision Medicine: Demaris Mills on IDT’s Role in Precision Medicine and Gene Synthesis for 2025

In a thought-provoking Q&A with BioPharma BoardRoom, Demaris Mills, President of Integrated DNA Technologies (IDT), discusses the transformative advanc...

December 12, 2024 | Thursday | Interaction
Shaping the Future of Gene Therapy: Kerstin Pohl on Analytical Innovations for 2025

In a detailed interview with BioPharma BoardRoom, Kerstin Pohl, Senior Global Marketing Manager for Gene Therapy & Nucleic Acid at SCIEX, delves into t...

December 12, 2024 | Thursday | Interaction
Pilatus Biosciences' PLT012 Receives Orphan Drug Designation for Liver and Intrahepatic Bile Duct Cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT0...

December 11, 2024 | Wednesday | News
Roche Presents Promising Data on Columvi® and Lunsumio® at ASH 2024, Advancing Treatment for Lymphoma

Roche (SIX: RO, ROG; OTCQX: RHHBY) that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presente...

December 11, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close